Effect of phenobarbitone on plasma lipids in normal subjects

Area of Science:

• Biochemistry
• Pharmacology
• Clinical Medicine

Background:

• Phenobarbitone is an antiepileptic drug with known effects on drug metabolism.
• Lipid metabolism alterations can have significant health implications.
• Understanding drug-induced changes in lipid profiles is crucial for patient management.

Purpose of the Study:

• To investigate the effects of phenobarbitone on plasma lipid profiles in healthy individuals.
• To assess changes in low-density-lipoprotein (LDL) and very-low-density-lipoprotein (VLDL) parameters.
• To examine the relationship between phenobarbitone-induced lipid changes and drug-metabolizing enzyme activity.

Main Methods:

• Ten healthy subjects received phenobarbitone 180 mg daily for 3 weeks.
• Plasma levels of total cholesterol, LDL cholesterol, LDL triglycerides, LDL protein, VLDL triglycerides, VLDL cholesterol, and VLDL protein were measured.
• Antipyrine clearance and serum gamma-glutamyl transpeptidase were assessed as markers of drug metabolism.

Main Results:

• Significant increases were observed in total plasma cholesterol, LDL cholesterol, LDL triglycerides, and LDL protein.
• The rise in total cholesterol was attributable to the increase in LDL cholesterol.
• A significant reduction in the ratio of LDL cholesterol to LDL protein was noted.
• No significant changes in VLDL parameters were detected.
• Increased antipyrine clearance indicated induction of drug-metabolizing enzymes.
• Elevated serum gamma-glutamyl transpeptidase was observed, unrelated to lipid changes or antipyrine clearance.

Conclusions:

• Phenobarbitone administration significantly alters lipid profiles, primarily by increasing LDL cholesterol and associated components.
• The drug induces hepatic drug-metabolizing enzymes, evidenced by increased antipyrine clearance.
• The observed lipid changes are independent of the degree of enzyme induction or changes in gamma-glutamyl transpeptidase levels.